6 天之前 · Right heart size differs between men and women with PAH: Study. Men with pulmonary arterial hypertension (PAH) have a larger right heart size and worse survival rates than women, independent of body size and functional status, a study reports.

2019年7月8日 · An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.

4 天之前 · The participants in HYPERION (NCT04811092) can now all choose to be treated with Winrevair as part of the open-label extension study SOTERIA (NCT04796337), according to the developer.. The decision to end the trial early was based on new positive data from another Phase 3 trial of Winrevair — early results that Merck said made continuing HYPERION unnecessary, and also not helpful for its ...

2025年1月22日 · People with pulmonary arterial hypertension (PAH) seen to be at an intermediate risk of death — whether in the low or high range of that middle-level risk — were more likely to have better outcomes when treated with Adempas (riociguat) than given a placebo in a Phase 3 clinical trial, its data show.

2024年12月16日 · An oxygen-sensing protein called hypoxia-inducible factor-1alpha, or HIF-1alpha, may contribute to worsening pulmonary arterial hypertension (PAH) and is a possible therapeutic target for people with this rare type of pulmonary hypertension, a study by Chinese scientists found.

2025年1月17日 · The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows. This regimen is “well-justified based on the totality of the observed safety and efficacy data from Phase ...

2024年12月20日 · In PAH, high blood pressure in the blood vessels that carry blood from the heart to the lungs results in symptoms like shortness of breath, fatigue, and chest pain. The disease can make even simple activities, like walking or climbing stairs, increasingly difficult and negatively impacts patients’ quality of life.

2024年4月3日 · First, in late March, the FDA approved a once-daily, fixed-dose tablet containing a combination of macitentan and tadalafil for adults with pulmonary arterial hypertension (PAH). It will be marketed under the brand name Opsynvi and is the first single-tablet treatment combination to become available to people with PAH in the U.S.. Then, just days later, the FDA approved the under-the-skin ...

2022年12月29日 · Opsumit (macitentan) is a daily oral therapy that’s approved to treat pulmonary arterial hypertension (PAH). In this study, researchers analyzed data from the Phase 3 clinical trial SERAPHIN (NCT00660179) and its open-label extension (NCT00667823) to evaluate the therapy’s long-term effect on survival.Nearly three-quarters (73.3%) of patients were alive at five years, and more than half ...

2024年10月2日 · Outcomes of PAH with CS1. The Phase 2 CS1-003 trial (NCT05224531) was designed to explore the safety, tolerability, and preliminary efficacy of CS1 on top of standard of care in 25 adults with PAH who were randomly assigned to receive one of three daily oral doses — 480 mg, 960 mg, or 1,920 mg — for 12 weeks, or about three months. The treatment was safe and well tolerated, meeting the ...